Production (Stage)
Travere Therapeutics, Inc.
TVTX
$15.84
$0.140.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 81.73M | 74.79M | 62.90M | 54.12M | 41.37M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 81.73M | 74.79M | 62.90M | 54.12M | 41.37M |
| Cost of Revenue | 51.57M | 64.62M | 53.31M | 56.39M | 50.92M |
| Gross Profit | 30.16M | 10.17M | 9.59M | -2.28M | -9.55M |
| SG&A Expenses | 72.84M | 69.50M | 65.62M | 64.78M | 64.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 124.41M | 134.12M | 118.92M | 121.17M | 115.15M |
| Operating Income | -42.67M | -59.33M | -56.03M | -67.05M | -73.77M |
| Income Before Tax | -41.19M | -60.34M | -54.84M | -69.57M | -135.77M |
| Income Tax Expenses | 39.00K | -72.00K | -84.00K | 85.00K | 191.00K |
| Earnings from Continuing Operations | -41.23M | -60.27M | -54.75M | -69.65M | -135.96M |
| Earnings from Discontinued Operations | -- | 4.00K | -59.00K | -757.00K | -103.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.23M | -60.26M | -54.81M | -70.41M | -136.06M |
| EBIT | -42.67M | -59.33M | -56.03M | -67.05M | -73.77M |
| EBITDA | -29.87M | -47.24M | -44.79M | -56.71M | -63.89M |
| EPS Basic | -0.47 | -0.73 | -0.70 | -0.91 | -1.76 |
| Normalized Basic EPS | -0.29 | -0.44 | -0.44 | -0.56 | -0.57 |
| EPS Diluted | -0.47 | -0.73 | -0.70 | -0.91 | -1.76 |
| Normalized Diluted EPS | -0.29 | -0.44 | -0.44 | -0.56 | -0.57 |
| Average Basic Shares Outstanding | 88.36M | 83.11M | 77.78M | 77.50M | 77.14M |
| Average Diluted Shares Outstanding | 88.36M | 83.11M | 77.78M | 77.50M | 77.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |